<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200217046524N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-05-25</date_registration>
      <primary_sponsor>Semnan University of Medical Sciences</primary_sponsor>
      <public_title>Assessment the effect of green tea and wheat bran on metabolic syndrome</public_title>
      <acronym></acronym>
      <scientific_title>Assessment the effect of green tea and wheat bran on diagnostic indicators of metabolic syndrome in Shahroud drivers in 2020</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-03-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/45929</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: Random allocation will be done using six Permuted Block Randomization methods. The total number of participants in this study is 90, which will be included in 3 groups of 30 people (2 intervention groups and one control group). 10 blocks of 6 will be determined and we will give each block from one to 10 numbers. Then, using the table of random numbers, 15 one-digit numbers (between 0 and 9) are selected completely randomly, and based on each of the selected numbers, a block is determined from the ten blocks (each of the randomly numbers will be corresponding to the same block number  except for the number zero which corresponds to the tenth block). Eligible individuals are assigned to three groups based on the arrangement of each block from left to right.</study_design>
      <phase>3</phase>
      <hc_freetext>Metabolic Syndrome.</hc_freetext>
      <i_freetext>Intervention 1: First intervention group: Green Tea- To the Green Tea Group will be recommended 3 cups of simple green teabag (one gram) daily from without added sugar or milk for 2 months. There will be provided from hygienic packaging products from Golestan brand with standard logo. Intervention 2: Second intervention group: Wheat bran- To the wheat bran group will be recommended 3.5 gram wheat bran powder based on individual taste with yogurt or rice daily for 2 months. There will be provided from hygienic packaging products of Nan Avaran brand with standard logo. Intervention 3: Control group: For the control group, 3 cups of water per day more than last daily consumption will be recommended.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data, protocols and forms of conscious consent can be shared (after individuals have been unrecognizable), .

When:
Start the access period 6 months after printing the results

To whom:
It will only be available to researchers working in academic and scientific institutions.

Conditions:
No analysis should be performed on the data.

Where to obtain:
Email: m.shayestefar@semums.ac.ir
Mina Shayestehfar - Faculty Member of Semnan University of Medical Sciences

How to obtain:
After reviewing the application and 6 months have passed since the results were published, the data will be sent within a week if the application of results are confirmed for the applicant.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mina Shayestefar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Semnan University of Medical Sciences, Basij Blvd, Semnan</address>
        <city>Semnan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3514799442</zip>
        <telephone>+98 23 3344 1022</telephone>
        <email>m.shayestefar@semums.ac.ir</email>
        <affiliation>Semnan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mina Shayestefar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Taavon street- first west 16 th- Fotros- 2th unit</address>
        <city>Semnan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3514774913</zip>
        <telephone>+98 23 3345 0193</telephone>
        <email>m.shayestefar@semums.ac.ir</email>
        <affiliation>Semnan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Satisfaction to participate in the study
Existence driver's health record
Metabolic syndrome based on ATP definition
Age range 40 to 50 years</inclusion_criteria>
      <agemin>40 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>A history of gastrointestinal disease
A history of liver disease
Being treated with corticosteroid drugs</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E88.81</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Metabolic syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>First intervention group: Green Tea- To the Green Tea Group will be recommended 3 cups of simple green teabag (one gram) daily from without added sugar or milk for 2 months. There will be provided from hygienic packaging products from Golestan brand with standard logo.</i_keyword>
      <i_keyword>Second intervention group: Wheat bran- To the wheat bran group will be recommended 3.5 gram wheat bran powder based on individual taste with yogurt or rice daily for 2 months. There will be provided from hygienic packaging products of Nan Avaran brand with standard logo.</i_keyword>
      <i_keyword>Control group: For the control group, 3 cups of water per day more than last daily consumption will be recommended.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Height. Timepoint: The measurement will be performed at baseline and before the intervention. Method of measurement: By the meter.</prim_outcome>
      <prim_outcome>Weight. Timepoint: Measurements will be taken at the beginning of the study before the intervention and will be repeated after 2 months and at the end of the intervention. Method of measurement: By a balance scales.</prim_outcome>
      <prim_outcome>Systolic &amp; Diastolic pressure. Timepoint: Measurements will be taken at the beginning of the study before the intervention and will be repeated after 2 months and at the end of the intervention. Method of measurement: By a Sphygmomanometer.</prim_outcome>
      <prim_outcome>Abdominal circumference. Timepoint: Measurements will be taken at the beginning of the study before the intervention and will be repeated after 2 months and at the end of the intervention. Method of measurement: By a meter.</prim_outcome>
      <prim_outcome>Fasting Blood Sugar. Timepoint: Measurements will be taken at the beginning of the study before the intervention and will be repeated after 2 months and at the end of the intervention. Method of measurement: By a Micro-plate Eliza Reader with Parsazmun kits.</prim_outcome>
      <prim_outcome>Triglycerides. Timepoint: Measurements will be taken at the beginning of the study before the intervention and will be repeated after 2 months and at the end of the intervention. Method of measurement: By a Micro-plate Eliza Reader with Parsazmun kits.</prim_outcome>
      <prim_outcome>High Density Lipoprotein. Timepoint: Measurements will be taken at the beginning of the study before the intervention and will be repeated after 2 months and at the end of the intervention. Method of measurement: By a Micro-plate Eliza Reader with Parsazmun kits.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Semnan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-02-04</approval_date>
        <contact_name>Ethics committee of Semnan University of Medical Sciences</contact_name>
        <contact_address>Semnan University of Medical Sciences, Basij Avenue Semnan Semnan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
